Compare NAAS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAAS | AYTU |
|---|---|---|
| Founded | 2019 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 25.7M |
| IPO Year | 2017 | 2015 |
| Metric | NAAS | AYTU |
|---|---|---|
| Price | $2.57 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 3.5K | ★ 45.8K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.41 | $0.95 |
| 52 Week High | $4.54 | $3.07 |
| Indicator | NAAS | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 54.63 |
| Support Level | $2.22 | $2.14 |
| Resistance Level | $3.43 | $2.66 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 51.43 | 60.87 |
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.